계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
AxioMx
About
AxioMx offers antibody discovery and development services for the research and diagnostics marketplace.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series Unknown
- Industries
- Biotechnology,Health Diagnostics,Marketplace
- Founded date
- Jan 1, 2012
- Number Of Employee
- 11 - 50
- Operating Status
- Active
AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 30, 2015 | Series Unknown | — | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advantage Capital
|
— | Series Unknown |
